ProMetic Life Sciences (TSE:PLI) will issue its quarterly earnings data after the market closes on Monday, April 1st.

TSE:PLI opened at C$0.31 on Wednesday. ProMetic Life Sciences has a 1-year low of C$0.25 and a 1-year high of C$1.36. The company has a debt-to-equity ratio of 238.62, a quick ratio of 0.99 and a current ratio of 1.52. The firm has a market capitalization of $222.62 million and a P/E ratio of -1.69.

PLI has been the topic of a number of analyst reports. TD Securities lowered shares of ProMetic Life Sciences from a “hold” rating to a “reduce” rating and lowered their price objective for the company from C$0.60 to C$0.30 in a research report on Thursday, December 20th. National Bank Financial upgraded shares of ProMetic Life Sciences from an “underperform” rating to a “sector perform” rating and set a C$0.45 price objective on the stock in a research report on Monday, January 28th.

COPYRIGHT VIOLATION WARNING: “ProMetic Life Sciences (PLI) Scheduled to Post Quarterly Earnings on Monday” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.

Featured Article: Quick Ratio

Earnings History for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with's FREE daily email newsletter.